Dr. Reddy's dream run during Covid-19
Dr. Reddy's, the second-largest pharmaceutical companies stock brought the cheers in the ordinary investor face. It proved with the correct timing and capital the stories and miracles do happen.
On 18th September 2020, the stock rallied over Rs.478.75 and at 2.15 pm it even peaked Rs.5477.60 from the days low of 4988.99.
Why the share price increased?
The drugmaker and Russian Direct Investment Fund (RDIF) agreed to cooperate on clinical trials and distribution of the Sputnik V vaccine in India. Upon regulatory approval in India, RDIF shall supply to Dr. Reddys 100 million doses of the vaccine.
Deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine by regulatory authorities in India, the statement added.
HDFC Securities had earlier this week upgraded Dr Reddy's to add, saying that growth visibility of the US business has improved with the strong momentum of new launches (12 launches in YTD FY21) including niche ones such as gCiprodex (first to market).
Sputnik V vaccine
On August 11, the Sputnik V vaccine developed by the Gamaleya National Research Institute of Epidemiology and Microbiology was registered by the Ministry of Health of Russia and became the world's first registered vaccine against COVID-19 based on the human adenoviral vectors platform.
The Sputnik V vaccine is undergoing clinical trials for the coronavirus pandemic
Public | |
Traded as | NSE: DRREDDY BSE: 500124 NYSE: RDY NSE NIFTY 50 Constituent |
ISIN | INE089A01023 |
Industry | Pharmaceuticals |
Founded | 1984 |
Founders | Anji Reddy |
Headquarters | Hyderabad, Telangana, India |
Area served | Worldwide |
Key people | G. V. Prasad (Co-Chairman & MD) Satish Reddy (Chairman) Erez Israeli (Chief Executive Officer) Saumen Chakraborty (Chief Financial Officer) |
Revenue | ₹17,460 crore (US$2.4 billion) (FY 2019-2020) |
₹1,950 crore (US$270 million) (FY 2019-2020)[1] | |
Total assets | ₹23,156 crore (US$3.2 billion) (March 2020) |
Total equity | ₹15,499 crore (US$2.2 billion) (March 2020) |
Number of employees | 21,966 (March 2019) |
Website | www |
Comments